MiMedx Group, Inc. has grown revenue 6.4% a year over three years and 6.4% a year over five. Revenue growth, 3-year annual rate: +6.4% (Biotechnology median +17%). Revenue growth, 5-year rate: +6.4%, growth has picked up over the last three years. Years of annual history on file: 16, FY2010 to FY2025, as filed.

MDXGMiMedx Group, Inc.

Healthcare

$4.61-37% 1Y

$4.61

$3.0952 weeks$7.96

Is it growing?

Watch

Growth is fading: revenue shrinking (−2% year on year), earnings down −81% year on year, and operating margin narrowing (−16.4 points).

3 to watch

Revenue trend−2% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +6% a year.

Earnings trend−81% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction−16.4 points operating

Trailing-twelve-month operating margin, -4.6% now against 11.8% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is MDXG growing?

MiMedx Group, Inc. has grown revenue 6.4% a year over three years and 6.4% a year over five.

+6.4%

Revenue growth, 3-year annual rate · Biotechnology median +17% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +6.4%
Revenue growth, 5-year rate · +6.4% over three · growth has picked up over the last three years
Years of annual history on file: 16
Years of annual history on file · FY2010 to FY2025, as filed

Details›